Britain approved a new oral Wegovy pill, but supply is uncertain. The UK regulator gave the green light today. Yet a cyber attack has already paused factory production. Patients waiting for the tablet face fresh delays as security teams work to restore output. This approval marks a major shift from injections to daily pills, but hackers have disrupted the very factories needed to fill prescriptions.
Oral Wegovy gets green light in Britain
The UK medicines regulator confirmed oral Wegovy is now approved for use today. This marks the first daily pill version of the weight-loss drug that previously required injections. Patients seeking treatment can finally choose a tablet instead of a needle starting this year.
The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation on 12 June, the government announced[1]. Britain becomes the first European country to clear this daily tablet form, Right Angled reports[7]. Only the US and UAE had approved it before this decision.
The pill contains semaglutide, the same active ingredient found in widely used injectable versions. It mimics a natural gut hormone released after eating to reduce hunger signals, medical data explains[7]. Patients must take a single dose once daily on an empty stomach with plain water.
Doctors say the drug may not work for everyone and requires a prescription from a specialist. While the approval brings hope, Novo Nordisk faces a separate crisis that could delay how fast patients get the medicine.
A cyber attack hits the factory floor
Novo Nordisk disclosed a significant cyber breach last week that disrupted its manufacturing systems. The attack forced the company to pause production at key facilities in Europe for several days. This stoppage means fewer doses of both injectable and oral Wegovy will reach UK pharmacies in the coming months.
A company spokesperson stated they are working with security experts to restore full operations. The breach affected internal networks but did not compromise patient medical records, according to initial reports. Staff at distribution centers now manually check stock due to system outages. One warehouse worker described the scene as a return to paper lists and clipboards.
Regulators approved the drug, but the company cannot yet guarantee the volume needed to meet sudden demand. It remains unclear exactly when normal shipping schedules will resume for the new oral tablets.
Patients face delays while security tightens
The approval brings hope, but the timeline for patients has shifted. Families waiting for the new tablet option must now prepare for potential shortages while systems recover. If you are prescribed this drug, your doctor may advise waiting or switching back to injections if stocks run dry.
When a global supplier suffers a cyber hit, even approved medicines can vanish from shelves without warning. This is not a failure of the science or the law. The UK regulator granted marketing authorisation for oral semaglutide on 12 June, the government confirmed[1]. The legal path is clear, yet the physical supply chain remains broken by digital sabotage.
Patients should check their current prescription status immediately. Ask your pharmacy about backup options before you attempt to refill. Novo Nordisk says it expects full recovery within weeks, but no specific date for the oral launch has been reset.
